Aptevo Theraoeutics has sold their recombinant factor IX product IXINITY® to Canada-based Medexus Pharmaceuticals. IXINITY®, which first received approval from the U.S. Food and Drug Administration (FDA) in 2015, is currently indicated for the control and prevention of bleeding episodes and for perioperative management in adults and children, 12 years of age or older, with hemophilia B.
“We are very pleased to announce this transformative acquisition,” said Ken d’Entremont, Chief Executive Officer of Medexus. “IXINITY® is an FDA approved product with strong brand equity and a track record of safety, efficacy and growing sales.”
Going forward Aptevo plans to focus on their proprietary technologies, including novel antibody-based immunotherapies the company is developing to treat cancer and other diseases.
Source: Medexus press release dated February 28, 2020
